COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,516 Articles (22,870 medRxiv, 8,646 bioRxiv)

Most recent first Previous |  Page 1556: Articles 15551-15560  | Next

Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch)
Shrotri, M., Fragaszy, E., Geismar, C., Nguyen, V., Beale, S., Braithwaite, I., Byrne, T. E., Fong, W. L. E., Kovar, J., Navaratnam, A. M. D., Patel, P., Rodger, A., Hayward, A. C., Aldridge, R. W.
10.1101/2021.05.12.21257102 — Posted: 2021-05-15
Distinct immune responses in patients infected with influenza or SARS-CoV-2, and in COVID-19 survivors, characterised by transcriptomic and cellular abundance differences in blood.
Legebeke, J., Lord, J., Penrice-Randal, R., Vallejo, A. F., Poole, S., Brendish, N. J., Dong, X., Hartley, C., Holloway, J. W., Lucas, J. S., Williams, A. P., Wheway, G., Strazzari, F., Gardner, A., Schofield, J. P. R., Skipp, P. J., Hiscox, J. A., Polak, M. E., Clark, T. W., Baralle, D.
10.1101/2021.05.12.21257086 — Posted: 2021-05-15
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 variants
Chen, Z.-N., Zhu, P., Bian, H., Geng, J., Chen, L., Yuan, Y., Chen, R., Wang, K., Deng, Y., Du, P., Liu, J., Wu, G., Wang, Y., Sun, X., Guo, T., Yang, X., Wu, J., Jiang, J., Li, L., Zhang, K., Zhu, H., Zheng, Z., Fu, X., Yang, F., Chen, X., Tang, H., Zhang, Z., Wei, D., Zhang, Y., Shi, Y., Zhu, Y., Pei, Z., Huo, F., Chen, S., Wang, Q., Xie, W., Li, Y.
10.1101/2021.05.14.444111 — Posted: 2021-05-15
Host transcriptional response to SARS-CoV-2 infection in COVID-19 patients
Singh, N. K., Srivastava, S., Zaveri, L., Bingi, T. C., Mesipogu, R., Kumar, S., Gaur, N., Hajirnis, N., Maccha, P., Shambhavi, S., Khan, S., Soujanya, M., Nagabandi, T., Mishra, R. K., Tallapaka, K. B., Sowpati, D. T.
10.1101/2021.05.13.443721 — Posted: 2021-05-15
COVID-19 outbreak rates and infection attack rates associated with the workplace: a descriptive epidemiological study
Chen, Y., Aldridge, T., UK COVID-19 National Core Studies Consortium, , Ferraro, C. F., Khaw, F.-M.
10.1101/2021.05.06.21256757 — Posted: 2021-05-14
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
Toback, S., Heath, P. T., Galiza, E. P., Baxter, D., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., Meyrick, A., Minassian, A. M., Minton, J., Moore, P., Munsoor, I., Nicholls, H., Osanlou, O., Packham, J., Pretswell, C., San Francisco Ramos, A., Saralaya, D., Sheridan, R. P., Smith, R., Soiza, R. L., Swift, P. A., Thomson, E. C., Turner, J., Viljoen, M. E., Albert, G., Cho, I., Dubovsky, F., Glenn, G., Rivers, J., Robertson, A., S
10.1101/2021.05.13.21256639 — Posted: 2021-05-14 Discussion: Onsite | Offsite
Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial
Patankar, S. B., Rangnekar, H., Joshi, K., Suryawanshi, K., Soni, P., Gorde, A., Shah, T., Patankar, S., Jha, D., Raje, R.
10.1101/2021.05.14.21256900 — Posted: 2021-05-14
Tyrosine Kinase Inhibitor Family of Drugs as Prospective Targeted Therapy for COVID-19 Based on In Silico And 3D-Human Vascular Lung Model Studies
Saxena, S., Meher, K., Rotella, M., Vangala, S., Chandran, S., Malhotra, N., Palakodeti, R., Voleti, S., Saxena, U.
10.1101/2021.05.13.443955 — Posted: 2021-05-14
in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617
Zhang, L., Huynh, T., Luan, B.
10.1101/2021.05.12.443826 — Posted: 2021-05-14
Glucosidase inhibitors suppress SARS-CoV-2 in tissue culture and may potentiate
Reyes, H., Du, Y., Zhou, T., Xie, X., Shi, P.-Y., Weiss, S. R., Block, T.
10.1101/2021.05.14.444190 — Posted: 2021-05-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).